Eurofins will provide contract validation and screening services for Celsis rapid detection technology
Eurofins Lancaster Laboratories, a specialist in bio/pharmaceutical GMP product testing, is to collaborate with Celsis International, a leader in rapid microbial detection systems, to provide more cost-effective rapid micro validation and screening services.
Under the agreement, Eurofins will provide contract rapid microbiology validation and screening services for the Celsis rapid detection technology platform.
Celsis says its rapid detection system allows companies to ensure that their products meet microbial specification 60–80% faster than traditional methods, reducing production cycle times by 7–10 days.
'The pharmaceutical industry has begun to embrace the cost savings that the Celsis method can bring to their operations,' said Judy Madden, Vice President of Corporate Development for Celsis. 'We’re working with some of the pharmaceutical industry’s leaders to implement the Celsis method for microbial limits and sterility testing but many don’t have the resources or expertise to complete the validation work required before implementation. Eurofins Lancaster Laboratories’ expertise in this area will ensure high-quality validations and streamline the implementation process for our customers.'